Physician profile
Madison Scott
NPI 1720675291
$4,861.62
in general payments reported to CMS, 2019-2025
22 companies · $1,051 in 2025
The $1,051 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $556 · 2023: $1,387 · 2024: $1,867 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,143 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,142.93 |
| Education | $162.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $929.68 | 2022-2025 | |
| Janssen Biotech, INC. | $592.53 | 2022-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $541.14 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $456.38 | 2022-2025 | Ilumya, Winlevi |
| Galderma Laboratories, L.P. | $421.82 | 2022-2025 | Nemluvio, Aklief |
| Amgen INC. | $316.59 | 2022-2025 | Otezla, Otezla |
| Leo Pharma INC. | $263.23 | 2022-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $249.86 | 2022-2023 | Sotyktu |
| Genzyme Corporation | $218.49 | 2023 | |
| Arcutis Biotherapeutics, INC. | $211.60 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $158.15 | 2023-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $105.23 | 2022 | |
| Organon LLC | $61.53 | 2024-2025 | Vtama |
| Dermavant Sciences, INC. | $60.95 | 2023-2024 | Vtama |
| Pfizer INC. | $54.14 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $54.04 | 2022-2024 | Olumiant |
| Incyte Corporation | $44.80 | 2023 | Opzelura |
| Ucb, INC. | $32.78 | 2022-2024 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.95 | 2022 | |
| Verrica Pharmaceuticals INC. | $23.75 | 2023 | Ycanth |
| Sandoz INC. | $19.24 | 2023 | Hyrimoz |
| Epi Health, LLC | $13.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.